ATOS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AT

Mkt Cap

$29.2M

Volume

99.79K

Next Earnings

November 11th

Loading chart

AT

ATOSAtossa Therapeutics, Inc. Common Stock

ATOS

Pay with—

Available Balance0.00

AT

Mkt Cap

$26.4M

Volume

99.79K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeDelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.GlobeNewswire Inc. · May 26, 2026

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateAtossa Therapeutics reported Q1 2026 results with total operating expenses of $9.9 million, up $2.5 million year-over-year. The company advanced its lead candidate (Z)-endoxifen across oncology and rare disease indications, securing FDA Orphan Drug Designation for DMD and Rare Pediatric Disease designations for both DMD and McCune-Albright Syndrome. The company strengthened its clinical leadership team and presented encouraging preclinical data for (Z)-endoxifen in DMD at the MDA conference.Benzinga · May 8, 2026

The Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyInstitutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.GlobeNewswire Inc. · Mar 19, 2026

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment ConferenceAtossa Therapeutics' CEO Dr. Steven Quay will participate in a fireside chat at the 27th Annual H.C. Wainwright Global Investment Conference, discussing clinical progress of their lead product (Z)-endoxifen, a potential breast cancer treatment and prevention therapy.Benzinga · Aug 28, 2025

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual SummitAtossa Therapeutics, a clinical-stage biopharmaceutical company, announced that its Vice President of Investor and Public Relations will participate in a virtual fireside chat at the 2024 Maxim Healthcare Virtual Summit.GlobeNewswire Inc. · Oct 14, 2024

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerSEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company. The study is investigating the combination as a neoadjuvant treatment in women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.GlobeNewswire Inc. · Jun 28, 2024

Are Medical Stocks Lagging Alvotech (ALVO) This Year?Here is how Alvotech (ALVO) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.Zacks Investment Research · Jun 25, 2024

Atossa Set to Join Russell 3000® Index Effective June 28, 2024SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.GlobeNewswire Inc. · Jun 17, 2024

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.Zacks Investment Research · Jun 6, 2024

Atossa to Present at the Sidoti Small-Cap Investor ConferenceSEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.GlobeNewswire Inc. · Jun 5, 2024

to start trading

AT

ATOSAtossa Therapeutics, Inc. Common Stock

ATOS

Pay with—

Available Balance0.00

Your PositionYou don't own any ATOS yet.

Related Tickers

Earnings